Novartis Q4 Results

↓ ↑ Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic Immunology Neuroscience Oncology Other Global Health Abbreviations References LeqvioⓇ - siRNA (regulation of LDL-C) LeqvioⓇ - siRNA (regulation of LDL-C) NCT03705234 ORION-4 (CKJX839B12301) Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients NCT05030428 VICTORION-2P (CKJX839B12302) Hypercholesterolemia inc. Heterozygous Familial Hypercholesterolaemia (HeFH) Indication Phase 3 16124 A composite of major adverse cardiovascular events, defined as: Coronary heart disease (CHD) death; Myocardial infarction; Fatal or non-fatal ischaemic stroke; or Urgent coronary revascularization procedure Arm 1: every 6 months treatment Inclisiran sodium 300mg (given by subcutaneous injection on the day of randomization, at 3 months and then every 6-months) for a planned median duration of about 5 years Arm 2: matching placebo (given bysubcutaneous injection on the day of randomization, at 3 months and then every 6 months) for a planned median duration of about 5 years. Patient population with mean baseline LDL-C ≥ 100mg/dL Phase Patients Primary Outcome Measures Arms Intervention Target Patients Readout Milestone(s) Publication Secondary prevention of cardiovascular events in patients with elevated levels of LDL-C Phase 3 16970 1. Time to First Occurrence of 3P-MACE (3-Point Major Adverse Cardiovascular Events) Arm 1: Experimental Inclisiran sodium, Subcutaneous injection Arm 2: Placebo Comparator, Placebo Subcutaneous injection Participants with established cardiovascular disease (CVD) 2027 TBD Readout Milestone(s) 2026 Publication TBD □ NOVARTIS Reimagining Medicine Novartis Q4 Results | January 31, 2024 50

View entire presentation